Opendata, web and dolomites

BETTER-B SIGNED

BETTER TREATMENTS FOR BREATHLESSNESS IN PALLIATIVE AND END OF LIFE CARE

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BETTER-B project word cloud

Explore the words cloud of the BETTER-B project. It provides you a very rough idea of what is the project "BETTER-B" about.

internationally    medicine    medicines    18    interstitial    randomised    widest    324    disease    cb    caregivers    obstructive    clinician    chronic    suggest    symptom    licenced    purpose    group    reviews    uk    unites    double    antidepressant    ild    despite    geriatric    conduct    carers    frightening    placebo    life    clinicians    tests    health    survey    guidance    copd    optimal    versus    breathlessness    underlying    italy    feasibility    physical    trial    recruits    germany    patient    society    clinical    time    rehabilitation    sustained    friends    pulmonary    months    alongside    accessible    services    groups    detrimental    morbidity    treatment    family    psychosocial    persists    operation    care    wellbeing    scientists    trialists    ireland    offers    patients    world    disciplinary    treating    quality    blind    refractory    mirtazapine    palliative    needing    reduce    economists    statisticians    distresses    community    lung    emergency    ensures    poland    respiratory   

Project "BETTER-B" data sheet

The following table provides information about the project.

Coordinator
KING'S COLLEGE LONDON 

Organization address
address: STRAND
city: LONDON
postcode: WC2R 2LS
website: www.kcl.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 3˙791˙503 €
 EC max contribution 3˙769˙999 € (99%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KING'S COLLEGE LONDON UK (LONDON) coordinator 1˙395˙122.00
2    UNIVERSITY OF LEEDS UK (LEEDS) participant 669˙111.00
3    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN IE (DUBLIN) participant 476˙203.00
4    AZIENDA UNITA SANITARIA LOCALE DI REGGIO EMILIA IT (REGGIO EMILIA) participant 283˙960.00
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 230˙812.00
6    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 170˙383.00
7    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN IE (DUBLIN) participant 109˙671.00
8    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 106˙095.00
9    GDANSKI UNIWERSYTET MEDYCZNY PL (GDANSK) participant 97˙612.00
10    UNIVERSITA CATTOLICA DEL SACRO CUORE IT (MILANO) participant 88˙987.00
11    UNIWERSYTET MIKOLAJA KOPERNIKA W TORUNIU PL (TORUN) participant 76˙290.00
12    EUROPEAN RESPIRATORY SOCIETY CH (LAUSANNE) participant 65˙750.00
13    UNIVERSITY OF TECHNOLOGY SYDNEY AU (SYDNEY) participant 0.00

Map

 Project objective

The BETTER-B consortium tests whether mirtazapine, currently used as an antidepressant, is an effective treatment to reduce chronic or refractory breathlessness (CB) in patients with advanced chronic obstructive pulmonary or interstitial lung disease (COPD or ILD) needing palliative care or at the end of life.

Our focus is on breathlessness that persists despite optimal treatment of the underlying condition. This widespread and frightening symptom has a major detrimental impact on patients’ quality of life and distresses their family, friends and carers. It is associated with physical and psychosocial morbidity and results in high use of health care services, including emergency care.

There are no licenced medicines for CB in the world. It is a major challenge to clinical management, care quality and patient wellbeing. We have completed a feasibility trial in 60 patients, reviews and case studies that suggest mirtazapine is a promising treatment.

To assess if mirtazapine is effective, we conduct a randomised double blind clinical trial of mirtazapine versus placebo in patients with CB and COPD or ILD. The trial recruits 324 patients over 18 months across respiratory, palliative care and community services in Poland, Ireland, Italy, Germany and the UK. We study the effects of treatment over time on patients, their family or caregivers and care costs. We survey clinicians and produce accessible European guidance on treating CB.

The consortium unites a unique multi-disciplinary group of clinician scientists from respiratory, palliative, geriatric and rehabilitation fields, alongside statisticians, trialists, health economists, health care researchers, patient and consumer groups and a European Society. This ensures the optimal design and operation of the trial and the widest impact from its results.

Using an existing medicine for a different purpose offers a highly cost-effective approach for treatment that can be implemented and sustained internationally.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETTER-B" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BETTER-B" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More